Last updated on April 2019

D-0120 Safety and PK/PD Study in China


Brief description of study

It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose, dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy subjects and hyperuricemia patients (gout or asymptomatic) in China.

Clinical Study Identifier: NCT03923868

Find a site near you

Start Over

Site 03

Nanjing, China
  Connect »

Site 07

Nanjing, China
  Connect »